Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Metoprolol is a selective beta-1 adrenergic receptor blocker (beta-blocker) used to treat hypertension (high blood pressure), angina pectoris (chest pain), heart failure, and to reduce mortality after myocardial infarction. It is also indicated for arrhythmias and prevention of migraine headaches. Metoprolol works by inhibiting beta-1 adrenergic receptors in cardiac tissue, leading to decreased heart rate and contractility as well as reduced cardiac output. This results in lower blood pressure and decreased oxygen demand by the heart. The drug is available in immediate-release (metoprolol tartrate) and extended-release (metoprolol succinate) formulations. Metoprolol was first developed in 1969 and approved for medical use in 1978.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metoprolol.